Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
51
GRFS Quote, Financials, Valuation and Earnings
Last price:
$9.02
Seasonality move
:
0.62%
Day range:
$8.97 - $9.18
52-week range:
$6.19 - $11.14
Dividend yield:
1.92%
P/E ratio:
14.70x
P/S ratio:
0.74x
P/B ratio:
2.67x
Volume:
240.5K
Avg. volume:
532.5K
1-year change:
15.47%
Market cap:
$6.1B
Revenue:
$7.8B
EPS (TTM):
$0.61
Analysts' Opinion
-
Consensus RatingGrifols SA has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.10, Grifols SA has an estimated upside of 22.92% from its current price of $9.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $9.03.
Fair Value
-
According to the consensus of 2 analysts, Grifols SA has 22.92% upside to fair value with a price target of $11.10 per share.
GRFS vs. S&P 500
-
Over the past 5 trading days, Grifols SA has underperformed the S&P 500 by -0.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Grifols SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Grifols SA has grown year-over-year revenues for 12 quarters straight. In the most recent quarter Grifols SA reported revenues of $2.2B.
Earnings Growth
-
Grifols SA has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Grifols SA reported earnings per share of $0.22.
Enterprise value:
19.6B
EV / Invested capital:
0.97x
Price / LTM sales:
0.74x
EV / EBIT:
13.03x
EV / Revenue:
2.36x
PEG ratio (5yr expected):
0.09x
EV / Free cash flow:
25.27x
Price / Operating cash flow:
7.93x
Enterprise value / EBITDA:
9.95x
Gross Profit (TTM):
$3.2B
Return On Assets:
2.24%
Net Income Margin (TTM):
6.15%
Return On Equity:
5.73%
Return On Invested Capital:
2.61%
Operating Margin:
18.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $6.6B | $7.6B | $8.3B | $2B | $2.2B | |
| Gross Profit | $2.5B | $2.9B | $3.2B | $798.4M | $857.4M | |
| Operating Income | $915.2M | $1.1B | $1.5B | $350.9M | $411M | |
| EBITDA | $1.4B | $1.6B | $2B | $470M | $531.1M | |
| Diluted EPS | $0.36 | $0.23 | $0.61 | $0.08 | $0.22 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $5.3B | $5.9B | $6.3B | |
| Total Assets | -- | -- | $23.4B | $22.6B | $23.3B | |
| Current Liabilities | -- | -- | $2.1B | $2.6B | $2.5B | |
| Total Liabilities | -- | -- | $14.3B | $13.7B | $14.5B | |
| Total Equity | -- | -- | $9.1B | $8.9B | $8.9B | |
| Total Debt | -- | -- | $10.9B | $9.9B | $10.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | $580.2M | $1.3B | $326M | $378.1M | |
| Cash From Investing | -- | $1B | -$670.6M | -$210.1M | -$150.3M | |
| Cash From Financing | -- | -$1.4B | -$548.1M | -$1.7B | -$168.8M | |
| Free Cash Flow | -- | $223.3M | $774.8M | $234.4M | $250.8M | |
GRFS
Sector
Market Cap
$6.1B
$28M
Price % of 52-Week High
81.06%
51.03%
Dividend Yield
1.92%
0%
Shareholder Yield
1.74%
-1.54%
1-Year Price Total Return
15.47%
-17.48%
Beta (5-Year)
0.671
0.518
Dividend yield:
1.92%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.01
200-day SMA
Buy
Level
$8.89
Bollinger Bands (100)
Sell
Level
8.85 - 10.11
Chaikin Money Flow
Buy
Level
64.9M
20-day SMA
Buy
Level
$8.93
Relative Strength Index (RSI14)
Buy
Level
53.26
ADX Line
Sell
Level
19.65
Williams %R
Neutral
Level
-35.8491
50-day SMA
Buy
Level
$8.97
MACD (12, 26)
Buy
Level
0.05
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
142.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.9621)
Sell
CA Score
(Annual)
Level (-1.1683)
Buy
Beneish M-Score
(Annual)
Level (-2.59)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.4917)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols i Roig in 1909 and is headquartered in Barcelona, Spain.
Stock Forecast FAQ
In the current month, GRFS has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The GRFS average analyst price target in the past 3 months is $11.10.
-
Where Will Grifols SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Grifols SA share price will rise to $11.10 per share over the next 12 months.
-
What Do Analysts Say About Grifols SA?
Analysts are divided on their view about Grifols SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Grifols SA is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Grifols SA's Price Target?
The price target for Grifols SA over the next 1-year time period is forecast to be $11.10 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is GRFS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Grifols SA is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of GRFS?
You can purchase shares of Grifols SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Grifols SA shares.
-
What Is The Grifols SA Share Price Today?
Grifols SA was last trading at $9.02 per share. This represents the most recent stock quote for Grifols SA. Yesterday, Grifols SA closed at $9.03 per share.
-
How To Buy Grifols SA Stock Online?
In order to purchase Grifols SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GRFS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GRFS
Sector
P/E ratio
14.70x
23.89x
PEG ratio
0.09x
-0.01x
P/B ratio
2.67x
1.82x
Price / LTM sales
0.74x
1.60x
Growth Metrics
GRFS
Sector
Revenue growth
10.67%
4.62%
Earnings growth
161.12%
10.88%
Revenue (5-year growth)
6.45%
6.5%
Earnings forecast
$0.28
-$0.21
Profitability
GRFS
Sector
Profitability FY 2024
$2.8B
$3.5M
Return on invested capital
2.61%
-31.77%
Return on assets
2.24%
-27.96%
Return on equity
5.73%
-37.63%
Earnings Date
Last Earnings Date
Jul
29
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Oct
28
Balance Sheet
GRFS
Sector
Total cash
$729.6M
$26.3M
Short term investments
$22M
$25.7M
Total assets
$22.2B
$78M
Long term debt
$10.7B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
